Johnson & Johnson is finding its footing after last week's retreat, but the borrow cost anomaly that defined the prior note has not resolved — and that tension remains the most interesting thread heading into October earnings.
The price action this week is a modest recovery. JNJ added roughly 1% on the week to close at what the ARS-denominated data shows as 27,300 — though it bears noting the snapshot is priced in Argentine pesos via the BASE exchange, which reflects a local listing rather than the NYSE price. The narrative arc from previous notes remains consistent: the stock bounced off the mid-July earnings trough near $247, rallied hard to $266, gave back ground through late July and early August to $256, and has since begun to stabilise. The mood has shifted from consolidation to tentative recovery.
The borrow market story remains unresolved. Last week's note flagged a striking anomaly: cost to borrow had surged to 0.678% by July 31, more than double the tight band of 0.19%–0.47% that persisted for most of the prior four months. That spike was the single largest weekly CTB move of the year. The critical question this week is whether that elevated borrow cost has persisted or receded — and the data available does not yet show a clean reversal. What made the spike anomalous then, and still makes it worth watching now, is its mismatch with everything else in the lending market: availability remains effectively unlimited, short interest sits at a low 1.22% of free float, and there is no squeeze mechanics in play. A borrow cost spike without availability tightening or short interest building points to idiosyncratic demand — someone paying up to establish or maintain a short position in a stock where borrowing is otherwise frictionless.
The factor score picture skews constructive. JNJ's dividend score ranks in the 90th percentile — consistent with a stock that has raised its payout reliably for decades and attracts income-focused institutional flows. The short score rank sits at the 71st percentile, reflecting modest but not alarming bearish positioning. Forward earnings momentum is reasonable, with the 12-month forward EPS year-on-year increase ranking in the 79th percentile and 30-day EPS momentum at the 60th. The drag, as flagged in prior notes, is valuation — though the multiples data in this snapshot is stale (2022 vintage) and cannot be quoted with confidence relative to current price levels.
Institutional ownership tells a passive-heavy story. BlackRock leads with 8.85% of shares, having added around 4.6 million shares in the most recent reported period through July 31. State Street added 1.5 million shares in the same window. JP Morgan Asset Management added 3.7 million shares through June 30. These are index-driven flows as much as active conviction, but the direction is consistent: large passive and quasi-passive holders are not reducing. Morgan Stanley is the one name trimming, cutting roughly 2.3 million shares as of March — a modest reduction from a mid-sized position. Capital Research, the active manager within the American Funds complex, added 3.1 million shares through May, which is a more deliberate signal of active conviction at current levels.
Earnings history offers limited but directional guidance. The most recent Q2 2026 print in mid-July produced a -1.1% next-day move, followed by a +1.7% five-day recovery — consistent with the broader arc of buy-the-dip behaviour that has characterised JNJ over several quarters. The prior quarter produced a sharper -4.7% one-day reaction. The next event is October 13, giving the stock roughly two months of runway to either re-establish price momentum or consolidate further before the next binary moment.
What to watch: whether the anomalous borrow cost spike from late July normalises back toward the 0.3%–0.4% range that defined most of 2026, or whether it reflects a more persistent shift in short-seller demand that the availability data has not yet caught up with.
See the live data behind this article on ORTEX.
Open JNJ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
